Delivery Order SPE2DR25D1202-SPE2DR26F73QC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Creon DR 36,000 Unit Capsules (100 count) with a ceiling value of $9,698.05. This firm fixed price delivery order, with an ultimate completion date of November 12, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract involves no set-aside designation and will be performed at the...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Creon DR 36,000 unit capsules in 100-count bottles, with a ceiling value of $2,424.24 and an ultimate completion date of June 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 12, 2025, for 24,000 unit capsules of Creon DR 100s with a ceiling value of $3,376.24. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of December 15, 2025. This delivery order represents a child...
- The Defense Logistics Agency awarded a $14,406.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for 36,000 unit capsules of Creon (pancrelipase) in 100-count packages, with completion scheduled for September 10, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award is non-set-aside and was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $6,150.38. This competitively awarded, firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Creon DR 36,000 unit capsules in quantities of 100s, with a ceiling value of $3,371.08 and a firm fixed-price structure. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Creon (pancrelipase) 36,000-unit capsules in 100-count bottles, with a ceiling value of $11,364.41 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of September 29, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 25, 2025, for the supply of Creon DR 36,000 Unit Capsules in units of 100s, with a contract value of $2,887.75. This non-set-aside, firm fixed-price delivery order is scheduled for completion by November 26, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement medication, with a ceiling value of $2,979.09. This is a firm fixed price delivery order with an ultimate completion date of December 3, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract was competitively awarded with no set-aside designation. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $10,494.25 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s on November 17, 2025, with completion expected by November 18, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of the vendor's pharmaceutical supply support to federal military and healthcare systems. The contract was executed under a non-set-aside procurement process, underscoring AmerisourceBergen's...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F73QCDelivery Order
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Creon DR 36,000 unit capsules in quantities of 100s. The contract was awarded on January 5, 2026, with a ceiling value of $7,378.99 and an ultimate completion date of January 6, 2026. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999.00 and runs through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp's DLA IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's track record demonstrates consistent capability to fulfill federal medical supply needs through open competition, with delivery orders ranging significantly in value and covering diverse therapeutic domains including specialty medications, vaccines, and specialized medical supplies. This delivery order for Creon DR—a pancreatic enzyme replacement therapy—represents a routine pharmaceutical procurement supporting military and federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 1/4/26 |